Earnings call
Lupin Q2 FY27 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company remains committed to FY27 margin guidance of around 24–25%, while recognizing that margins are likely to moderate in the coming quarters because of intensifying competition in some key U.S. products, increased investment in its R&D pipeline, and higher input costs arising from the challenging macroeconomic environment in the Middle East. Pipeline includes more than 55 injectable and respiratory products under active development. India business grew 14.7% YoY in Q2 FY27, while its core prescription business grew 13.8%, aided by volume growth of 6%. IPM market growth reached a six-quarter high of 14.7% in Q2. Chronic therapies accounted for around 66% of its portfolio, up from around 65% in FY26, and the company aims to increase this share to 70% over the next five years.
The numbers management gave
Results
- India business grew 14.7% YoY in Q2 FY27, while its core prescription business grew 13.8%, aided by volume growth of 6%.
Show source
Turning to India, our business delivered 14.7% YoY growth this quarter, with the core prescription business growing 13.8% aided by volume growth of 6%.
- Prescription business grew 14.4% in the first half, compared with 14.3% growth in the IPM.
Show source
For the first half, our prescription business grew 14.4%, compared with 14.3% growth in the IPM.
- Chronic segment grew 19.5% in Q2 FY27, ahead of the IPM’s 17.2% growth.
Show source
Our chronic segment grew 19.5%, ahead of the IPM’s 17.2% growth.
- Anti-Diabetes and Cardiac segments grew at 1.5x and 1.1x their respective category growth rates in the first half.
Show source
In the first half, our Anti-Diabetes and Cardiac segments grew at 1.5x and 1.1x their respective category growth rates.
- Diabetes segment delivered 25% plus YoY growth in Q2 FY27, its third consecutive quarter of 20% plus growth.
Show source
Our Diabetes segment was a particular highlight, delivering 25% plus YoY growth this quarter— our third consecutive quarter of 20% plus growth .
- Other Developed Markets —Europe, Canada, and Australia—delivered 46% YoY sales growth in Q2 FY27 and accounted for 15% of its revenues, compared with 11% in FY26 and 14% in Q1FY27; revenues were INR 1,182 crores in Q2 FY27, representing growth of around 46% YoY.
Show source
Other Developed Markets As far as Other Developed markets are concerned, revenues in our other developed markets were INR 1,182 crores, representing a growth of around 46% YoY.
Show 27 more statements
Results
- European business grew 45% YoY in Q2 FY27.
Show source
Within this, our European business sustained strong momentum, with 45% YoY growth.
- R&D investment was 7.9% of sales in Q2 FY27, focused on complex and specialty platforms.
Show source
R&D remains central to our growth strategy, with investment at 7.9% of sales this quarter focused on complex and specialty platforms.
- U.S. business recorded sales of USD 317 million in Q2 FY27, a decline of 13.4% QoQ on constant currency basis, largely due to increased competition and Loss of Exclusivity on Mirabegron and Tolvaptan, partially offset by seasonal demand and volume growth in select products.
Show source
U.S Business Speaking about the U.S. business, this quarter, the U.S. business recorded sales of USD 317 million, a decline of 13.4% QoQ on constant currency basis.
- Core prescription business grew 13.8% YoY in Q2 FY27 and 14.4% YoY during H1.
Show source
Within this, our core prescription business grew 13.8% YoY and 14.4% YoY during the quarter and H1, respectively.
- Diabetes, Cardiology and Dermatology segments grew at 1.5x, 1.1x, and 1.5x their respective category growth rates during the first six months, while volume growth was 6.1% during the same period.
Show source
Key segments like Diabetes, Cardiology and Dermatology handsomely outperformed their category growing at 1.5x, 1.1x, and 1.5x respectively during the first six months while volume growth has been a healthy 6.1% during the same period.
- Other Emerging markets de-grew by 4% YoY in Q2 FY27, as lower sales in Brazil offset double digit growth in South Africa, Philippines, and Mexico.
Show source
Other Emerging Markets Other Emerging markets de-grew by 4% YoY in the quarter, with lower sales in Brazil offsetting double digit growth in key markets like South Africa, Philippines, and Mexico.
- Other Operating Income was INR 42 crores in Q2 FY27, compared with INR 216 crores in Q2FY26, a decrease of around 81% YoY primarily due to lower export benefits from the PLI schemes during the quarter.
Show source
Coming to the P&L. Other Operating Income Page 5 of 15 November 4, 2026 Other Operating Income at INR 42 crores as against INR 216 crores in Q2FY26, has decreased around 81% YoY, primarily due to lower export benefits from the PLI schemes during the quarter.
- Gross margins were 74.2% in Q2 FY27, compared with 73.3% last year and 74.6% in Q1; sequential margins benefited from increased volumes, cost initiatives, and higher profitability in India, while increased competitive intensity on key U.S. products and elevated geopolitical risks in the Middle East weighed on margins.
Show source
Gross Margins Gross margins came in at 74.2% as compared to 73.3% last year and 74.6% in Q1.
- Employee benefit expenses were INR 1,424 crores in Q2 FY27, up around 29% YoY from INR 1,106 crores in Q2FY26, and represented 18.3% of sales compared with 16.2% in Q2 last year; the increase was largely attributable to regular annual increments and business growth during the period.
Show source
Employee Benefit Expenses Employee benefit expenses at INR 1,424 crores increased around 29% YoY from INR 1,106 crores in Q2FY26, translating to 18.3% of sales as compared to 16.2% in Q2 last year.
- Manufacturing and other expenses were INR 2,438 crores in Q2 FY27, up around 23% YoY from INR 1,980 crores in Q2FY26, and represented 31.3% of sales versus 29.0% last year; expenses were higher mainly due to higher volumes in the normal course of business, higher SG&A expenses from field force expansion, and license fee payments as part of settlement agreements.
Show source
Manufacturing & Other Expenses Q2FY27 manufacturing and other expenses came in at INR 2,438 crores, increasing around 23% YoY from INR 1,980 crores in Q2FY26, translating to 31.3% of sales versus 29.0% last year.
- R&D expenses were INR 618 crores, or 7.9% of sales, in Q2 FY27, compared with INR 522 crores in Q2 last year.
Show source
R&D R&D at INR 618 crores is 7.9% of sales as compared to INR 522 crores in Q2 last year.
- R&D expenses were INR 1,226 crore, representing 7.7% of sales, on an H1 basis.
Show source
On an H1 basis, R&D was INR 1,226 crore representing 7.7% of sales.
- EBITDA excluding Forex and other income was INR 1,957 crores in Q2 FY27, compared with INR 2,138 crores in the same period last year, with a margin of 25.1% versus 31.3% in the same period.
Show source
EBITDA EBITDA excluding Forex and other income was INR 1,957 crores vis-a-vis INR 2,138 crores in the same period last year with a margin of 25.1% vis-a-vis 31.3% last year in the same period.
- Foreign-exchange forwards taken in the first quarter were around 89 to 90 when the year started; they depressed overall realizations in the first quarter, an effect that was not present in the second quarter and provided tailwinds in the second quarter.
Show source
It had depressed overall realizations for the first quarter, which is not there in the second quarter.
- The company was 16% ahead of the market for H1, but not where it needed to be; slow respiratory growth was pulling down the average, cardiac had slowed a little, and diabetes was excelling.
Show source
Nilesh Gupta: For H1, we are 16% ahead of the market, but definitely not where we need to be.
- Chronic value growth was 19.5% in H1 and 17.4% in Q2; the chronic segment grew 19.5% in H1 versus IPM growth of 17.2%, and the chronic share in its mix increased to around 66% in H1FY27 from around 65% in FY26.
Show source
The chronic segment grew 19.5% in H1 vs IPM growth of 17.2% and the chronic share in the mix has increased to around 66% in H1FY27 from around 65% in FY26.
- Overall MAT volume growth was 8.6%, and H1 volume growth was 6.1%.
Show source
Overall, MAT volume is 8.6%, and H1 was 6.1% volume growth.
- Organic revenue growth remained in double digits in Q2 FY27, driven by performance in India and Other Developed Markets.
Show source
Our organic revenue growth remained in double digits, driven by strong performance in India and Other Developed Markets.
- Base portfolio benefited from higher volumes and contributions from seasonal products in Q2 FY27, but those gains were offset by pricing pressures in certain products, particularly Tolvaptan.
Show source
While our base portfolio benefited from higher volumes and contributions from seasonal products, these gains were offset by pricing pressures in certain products, particularly Tolvaptan.
- Diabetes segment performance was led by its market leadership in Huminsulin® and the successful launch of Semaglutide injection.
Show source
This performance was led by our market leadership in Huminsulin® and the successful launch of Semaglutide injection.
- Europe business was strong, with double digit growth even without VISUfarma.
Show source
Vinita Gupta: Europe was pretty strong, double digit, even without VISUfarma.
- Additional competition in Dapagliflozin in Latin America and Brazil was primarily the reason for the decline in Lupin Limited's Emerging Market revenues.
Show source
That was primarily the reason for the decline in Emerging Market revenues.
- Expenditure increase is essentially due to Mirabegron settlement-related costs, which would reverse out.
Show source
Ramesh Swaminathan: The expenditure increase is essentially because of settlement-related costs on account of Mirabegron which would reverse out.
- Chronic segment grew 19.5% in H1 versus IPM growth of 17.2%, and the chronic share in its mix increased to around 66% in H1FY27 from around 65% in FY26. Replaced by a later filing.
- Revenues in its other developed markets were INR 1,182 crores in Q2 FY27, representing growth of around 46% YoY. Replaced by a later filing.
Money and capital
- Net cash stood at INR 3,349 crores as against INR 4,636 crores on 31st March 2026, largely due to the closure of its VISUfarma acquisition and dividend payouts this year.
Show source
Net Cash Page 6 of 15 November 4, 2026 Net cash stood at INR 3,349 crores as against INR 4,636 crores on 31st March 2026 largely due to the closure of our VISUfarma acquisition and dividend payouts this year.
- The company would keep its overall capital threshold at twice EBITDA, potentially allowing about INR 16,000 crore – INR 17,000 crore for debt and about INR 3,000 crore – INR 4,000 crore on its balance sheet, and could go up to INR 20,000 crore if the proposition is compelling enough.
Show source
So that would potentially mean about INR 16,000 crore – INR 17,000 crore for debt, and about INR 3,000 crore – INR 4,000 crore that we have on our balance sheet.
What it expects ahead
What management expects
- The company remains committed to FY27 margin guidance of around 24–25%, while recognizing that margins are likely to moderate in the coming quarters because of intensifying competition in some key U.S. products, increased investment in its R&D pipeline, and higher input costs arising from the challenging macroeconomic environment in the Middle East.
Show source
We remain committed to our FY27 margin guidance of around 24–25%, while recognizing that margins are likely to moderate in the coming quarters.
- The company continues to expect U.S. revenues of USD 1.1 billion to USD 1.2 billion for FY27.
Show source
For FY27, we continue to expect U.S. revenues in the range of USD 1.1 billion to USD 1.2 billion.
- The company is on track to file more than 15 products during the current fiscal.
Show source
We are on track to file more than 15 products during the current fiscal.
- The company expects to launch more than 60 products in the U.S. over the next three years, including approximately 25 injectable and respiratory products, 5 biosimilars, and 2 – 3 505(b)(2) products.
Show source
Over the next three years, we expect to launch more than 60 Page 2 of 15 November 4, 2026 products in the U.S., including approximately 25 injectable and respiratory products, 5 biosimilars, and 2 – 3 505(b)(2) products.
- The company expects its India formulations business to grow at 1.2x to 1.3x the IPM growth rate, supported by a prescription sales force of nearly 11,400 people and a pipeline of more than 80 new product launches over the coming years.
Show source
We are well positioned to capitalize on this momentum and remain confident that our India formulations business will grow at 1.2x to 1.3x the IPM growth rate, supported by our prescription sa les force of nearly 11,400 people and a pipeline of more than 80 new product launches over the coming years.
- The company is preparing to file 4 – 5 biosimilars for the U.S. market over the next few years.
Show source
We are also preparing to file 4 – 5 biosimilars for the U.S. market over the next few years.
Show 40 more statements
What management expects
- The company expects product launches from its 505(b)(2) pipeline to begin this fiscal year, with a potential launch of Apixaban Oral Suspension in FY28.
Show source
We have built a strong 505(b)(2) pipeline, with product launches expected to begin this fiscal year and a potential launch of Apixaban Oral Suspension in FY28.
- The company expects to be in the first wave for Etanercept in 2029.
Show source
Vinita Gupta: We expect to be in the first wave in 2029.
- The company does not expect products like semaglutide and other newer peptides, the GLP-1s, to reach the market anytime soon because their patent expiry is beyond the five-year timeframe.
Show source
We don't expect to get products like semaglutide and others, the newer peptides, the GLP-1s, into the market anytime soon , just given the patent expiry is beyond the five-year timeframe for those products.
- Investments in specialty, particularly in Europe, biosimilars and 505(b)(2)s give Lupin confidence it can evolve its developed markets business toward a more durable and sustainable portfolio rather than one-off exclusives.
Show source
Investments in areas like specialty, particularly in Europe, as well as biosimilars and 505(b)(2)s, give us confidence that we should be able to evolve our developed markets business toward a more durable and sustainable portfolio, as opposed to one -off exclusives.
- The company expects its ETR to be around 20-21% for the full year.
Show source
We expect this momentum to continue into the second half of the year, with organic growth of around 20% excluding U.S. On profitability, we delivered EBIDTA margins of around 25% during the quarter, despite increased investments in R&D and a challenging geopolitical and operating environment.
- The company targets novel proprietary products contributing one third of its India revenues in the next 10-year timeframe.
Show source
Looking further ahead, our target is for novel proprietary products to contribute one third of our India revenues within the next 10 years.
- The company plans to launch 20+ products in India in FY27.
Show source
We have launched 12 products in H1FY27 and plan to launch about 20 products in FY27, vis-a-visa 15 products which we had launched in FY26.
- The company expects R&D to be around 8% for the full year.
Show source
For the full year, as indicated, we expect R&D to be around 8%.
- The company expects EBITDA margins of around 24% - 25% next year, with some products sustaining momentum.
Show source
For the full year, as indicated in our earlier interaction, we expect EBITDA margins to be around the 24%-25%.
- The company expects its effective tax rate to be in the region of 27% - 28% for the full-year.
Show source
For the full-year, we expect ETR to be around 27%-28% Balance Sheet Operating Working capital Operating working capital stands at INR 7,542 crores as of 30th September, against INR 7,132 crores as of 31st March'26, which translates to 87 days of working capital against 90 days in the previous quarter.
- The company expects its India business to grow 20% - 30% ahead of the market.
Show source
Our goal is 20%-30% ahead, so we are short of that.
- The company expects competition in Tolvaptan to increase further, with the possibility of additional entrants over the coming quarters.
Show source
We expect competitive intensity in Tolvaptan to increase further, with the possibility of additional entrants over the coming quarters.
- The company expects growth in its base business, new injectable launches, and contributions from Pegfilgrastim to help offset the impact of increasing competition in key products.
Show source
Growth in our base business, new injectable launches, and contributions from Pegfilgrastim are expected to help offset the impact of increasing competition in key products.
- The company expects the commercial launch of its biosimilar portfolio in the U.S. this year and an anticipated launch of Apixaban Oral Suspension, for which it received tentative approval in Q2 FY27, to offset short-term U.S. business impact.
Show source
This will be offset by the commercial launch of our biosimilar portfolio in the U.S. this year and from the anticipated launch of Apixaban Oral Suspension for which we received tentative approval this quarter.
- The company expects to launch Apixaban in the first quarter of FY28 and expects its share to build up as it gains traction in its targeted channels.
Show source
We expect to launch the product in the first quarter of FY28, and as we gain traction in the channels that we have targeted, we expect the share to build up.
- The company expects revenue to remain at a billion dollars plus, a level it wants to maintain.
Show source
Vinita Gupta: Revenue should remain at a billion dollars plus, which is a bar that we want to be able to maintain.
- The company said additional competition on Tolvaptan is a pressure in matching FY27 levels.
Show source
In terms of matching levels of FY27, we have some pressures with Tolvaptan coming off with additional competition.
- The company expects additional competition on Mirabegron post-September next year.
Show source
Post - September next year, we would expect additional competition on Mirabegron.
- The company expects Apixaban, Dalbavancin and biosimilars, particularly Pegfilgrastim, to help it grow.
Show source
Apixaban, Dalbavancin and the biosimilars, particularly Pegfilgrastim, should help us grow.
- The company hopes to be at least at a billion dollars plus.
Show source
We hope to be able to be at least at a billion dollars plus.
- The company expects its business to grow in FY29 with the full-year impact of some of its more durable pipeline products.
Show source
As we look out in FY29 and get the full-year impact of some of these more durable pipeline products, we would expect the business to grow.
- The company expects potentially a couple of additional competitors to enter the Tolvaptan market.
Show source
Vinita Gupta: We expect potentially a couple of additional competitors can come in.
- The company expects to give up some Tolvaptan share with additional competition, while generic share continues to grow; it expects margin contribution and revenue contribution to come down significantly, with the bigger impact on pricing.
Show source
We would expect the generic share to continue to grow, and we are certainly continuing to maintain a big percentage of our channel partners but would expect the margin contribution and revenue contribution to come down significantly.
- The company is planning additional investments in the next couple of quarters to build market access, channel expertise and relationships for Apixaban and build share in the exclusive window before generics enter.
Show source
Vinita Gupta: Yes, we are planning to make additional investments in the next couple of quarters to be able to get the right market access and channel expertise and relationships to be able to build share in the exclusive window that we have prior to the generics coming in.
- The company expects to retain some Apixaban share after generics enter in segments that benefit from a liquid dosage form.
Show source
In particular, we would expect to retain some Page 9 of 15 November 4, 2026 share after the generics come in segments that benefit from a liquid dosage form.
- The company expects its differentiated dosage product to be more durable after generics enter in FY29.
Show source
Vinita Gupta: That is what we are expecting .
- The company expects its respiratory business to pick up in the second half.
Show source
There is no sense in this pattern, but I do see it picking up in second half.
- The company said the Xywav® opportunity is further out than FY29.
Show source
Vinita Gupta: It is not FY29; it is a further -out opportunity.
- The company expects Diazepam nasal spray for certain and hopes for Dulera, depending on the queries it receives from the FDA; it hopes the opportunity will be next year or early FY29.
Show source
Vinita Gupta: We are expecting Diazepam for certain, and hopefully Dulera also, depending on the queries we get from the FDA.
- The company expects to retain Apixaban share, especially in channels where the liquid dosage form brings real benefit to patients, and hopes to have a tail in the coming years.
Show source
The time we have prior to generics coming in is likely the most valuable, but we expect to retain share, especially in channels where the liquid dosage form brings real benefit to patients.
- The company expects an EBITDA margin like an exclusive product, with some investment on the commercial front.
Show source
We are expecting a margin like an exclusive product, but with some investment on the commercial front.
- The company said Sugammadex, which it just launched, is a nice opportunity.
Show source
Sugammadex that we just launched is a nice opportunity for us.
- The company sees a larger opportunity in biosimilars than in injectables over the next three to five years.
Show source
We see larger opportunity on the biosimilars front, even compared to injectables in the next three to five years.
- The company expects some niche product launches on the iron colloid side.
Show source
Vinita Gupta: We expect some niche product launches on the iron colloid side as well.
- The company expects IT spends to increase over three to four years but be much lower as a percentage of sales.
Show source
So, if you were to take a period of time, say three, four years, you would expect the IT spends would increase, but as a percentage of sales, to be much lower.
- The company looks at the next year as a year of investment and capability building to create a more resilient business.
Show source
We remain excited about our prospects over the next five years and look at the next year as a year of investment and capability building to create a more resilient business.
- The company remains on track to achieve its FY27 revenue growth and profitability goals as it navigates an increasingly competitive and challenging operating environment. Replaced by a later filing.
Show source
In closing, we remain on track to achieve our FY27 revenue growth and profitability goals as we navigate an increasingly competitive and challenging operating environment.
- The company said it has new launches, its business is doing well, and its entire chronic share is solid; it would expect to build back growth. Replaced by a later filing.
Show source
We would expect to build back growth.
- The company plans to ramp up its biosimilar products over the next few years as biosimilars see active adoption in the marketplace. Replaced by a later filing.
Show source
We are very pleased that we are going to ramp up these products over the next few years at a time when there is significant openness relative to five to eight years ago.
- Q2 and Q1 were above plan, and it will maintain its guidance and see if it gets any upside. Replaced by a later filing.
Show source
Therefore, we will maintain our guidance and see if we get any upside.
What it is building and selling
Projects and capacity
- Pipeline includes more than 55 injectable and respiratory products under active development.
Show source
Our pipeline includes more than 55 injectable and respiratory products under active development.
- The company has filed both the injectable generic version and a 505(b)(2) version of Dalbavancin.
Show source
Dalbavancin, both the 505(b)(2) as well as generic opportunities are nice opportunities for us.
- The company has completed exhibit batches for Spiriva Respimat and expects to file it this fiscal year.
Show source
Vinita Gupta: We have made really good progress on Respimat ; exhibit batches are done, and the filing is this fiscal year on Spiriva Respimat ®.
- The company expects to file the Breo product later this fiscal year, although the filing may slip a couple of months into first quarter next fiscal year.
Show source
On the Ellipta franchise, we have had good progress on the Breo product, so that is expected to be filed later this fiscal year.
- Seven to eight products targeted across the Respimat and Ellipta platforms and MDIs remain on track to be filed within this fiscal year or within a couple of months of the end of the fiscal year.
Show source
It probably will slip a couple of months into first quarter next fiscal year, but the seven to eight products that we targete d with these two plus the MDIs remain on track to be filed within this fiscal year or within a couple of months of the end of the fiscal year .
Demand and pricing
- IPM market growth reached a six-quarter high of 14.7% in Q2.
Show source
The IPM market growth reached a six -quarter high of 14.7% in Q2.
Show 11 more statements
Demand and pricing
- The company had 50% market share in Tolvaptan in the last couple of months while it was the sole generic in the marketplace.
Show source
We had market share of 50% in the last couple of months, being the sole generic in the marketplace.
- U.S. business was significantly impacted in the short term by increased competitive intensity on some key products.
Show source
While we continue to benefit from our differentiated strategy on focusing on complex products, as indicated in our earlier interaction, we see the U.S. business significantly impacted in the short term from the increased competitive intensity on some of these key products.
- Inhalation side, including MDI, DPI, and nebulization, was slower in the respiratory business.
Show source
Our focus is on the inhalation side, MDI, DPI, and nebulization, and that part has been slower.
Segments
- Chronic therapies accounted for around 66% of its portfolio, up from around 65% in FY26, and the company aims to increase this share to 70% over the next five years.
Show source
Chronic therapies now account for around 66% of our portfolio, up from around 65% in FY26, and we aim to increase this share to 70% over the next five years.
- The company believes it was sole exclusive and first to file for Xywav®.
Show source
We believe we were sole exclusive and first to file.
- The company said its Semaglutide number was not very large in volume and that it was the third-largest generic.
Show source
We are the third-largest generic, but the Semaglutide number is not very large in that volume.
- Products launched so far in peptides are Glucagon and Liraglutide, which it expects to remain the material products over the next couple of years.
Show source
Vinita Gupta: On peptides, the products launched so far are Glucagon and Liraglutide.
- The company said Risperdal Consta® is one of its injectable products turning out to be really attractive.
Show source
Risperdal Consta® is one of them.
- The company has entered the ophthalmic space and would like to grow in that space across the globe. Replaced by a later filing.
Show source
Ramesh Swaminathan: We have entered the ophthalmic space and would like to grow in that space across the globe.
Deals and partners
- The company entered an exclusive licensing partnership with Tenpoint Therapeutics during Q2 FY27 to commercialize Yuvezzi ™ in Europe.
Show source
During the quarter, we entered an exclusive licensing partnership with Tenpoint Therapeutics to commercialize Yuvezzi ™ in Europe.
- The company launched Pegfilgrastim through its partner Valorum and looks forward to learning from that experience.
Show source
Vinita Gupta: Our first one, Pegfilgrastim, has launched through our partner Valorum, so we look forward to learning from that experience.
Risks, rules and outside factors
Risks and disputes
- The company has submitted its responses for Pithampur Unit II and remains on track with its remediation efforts.
Show source
At Pithampur Unit II, we have submitted our responses and remain on track with our remediation efforts.
Rules and policy
- The company (Lupin) received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.
Show source
The tentative Page 3 of 15 November 4, 2026 approval of our novel Apixaban Oral Suspension through the 505(b)(2) pathway during the quarter underscores the strength of our R&D capabilities.
- The company was approved for the first green propellant MDI in India this past week.
Show source
We were very pleased to get approved for the first green propellant MDI in India this past week.
Everything else said on the call
What management stressed
- Priority is to double the share of complex products in its U.S. portfolio, with respiratory products, complex injectables, and biosimilars as key growth drivers.
Show source
Our priority is to double the share of complex products in our U.S. portfolio, with respiratory products, complex injectables, and biosimilars serving as key growth drivers.
- The company is investing to build scale in India, enhance its specialty capabilities in Europe, and tap biosimilar opportunities in the US.
Show source
We are investing on multiple fronts, including building scale to capture the growth opportunities in India, enhancing our specialty capabilities in Europe, and tapping the growing biosimilar opportunities in the US.
- The company is investing ahead of the curve in IT, including a number of platforms and AI spends.
Show source
The second is, we are also investing ahead of the curve in terms of IT, a number of platforms and Al spends.
- The company will build its novel proprietary product portfolio through in-house development and in-licensing. Replaced by a later filing.
Show source
We will build this portfolio through in -house development and in -licensing, drawing on our partnership track record and our brand-building, development, regulatory and clinical capabilities.
- The company continues to explore strategic allocation of its capital, including on the specialty front. Replaced by a later filing.
Show source
Whilst we focus on increased cash generation for our business, we would like to highlight that we continue to explore strategic allocation of our capital to ensure the long-term mission of the company, including on the specialty front.
- Consistent performance and increased investment in India continue to be a strong anchor for growth. Replaced by a later filing.
Show source
Our consistent performance and increased investment in India continue to be a Page 14 of 15 November 4, 2026 strong anchor for growth.
Show 1 more statement
Group structure
- The company says it will be judicious in its investment choices, with specialty in Europe and America as its first choice and acquisitions in India receiving equal importance only at a cost appropriate from its perspective.
Show source
Our first choice would be specialty in Europe and America, and equal importance to acquisitions in India, but only at a cost appropriate from our perspective.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Dhara Ganatra: My question was on the gross margin front. As Tolvaptan and Mirabegron were exclusive products and have come off in this quarter, we are clearly seeing that in the decline in revenues, but the same impact has not been reflected on the gross margin side. What is the other offsetting factor that explains this?
Answer, vinita gupta
Vinita Gupta: I just wanted to clarify that the decline is primarily in Tolvaptan. Mirabegron has been relatively stable. Please go ahead, Ramesh.
Answer, ramesh swaminathan
Ramesh Swaminathan: It is clearly because of that in the Americas, but there is a mix change in other parts. Moreover, there have been tailwinds in terms of forex associated with the impact on gross margins, and that is the reason why you actually say that the gross margins are more or less slightly on the higher side vis-a-vis the previous quarter. I mean, vis-a-vis the previous quarter, there is a decline, but it is not so steep.
Question
Shashank Krishnakumar: Just wanted to understand on Apixaban, typically the way reimbursement works for some of these 505(b)(2) products. There could be a few challenges with respect to getting reimbursement codes assigned and then getting coverage. Do you anticipate any of those challenges post-launch in the first few months? Could there be a lag in terms of the product gaining traction and revenue getting recognized?
Answer, vinita gupta
Vinita Gupta: The differentiated products, 505(b)(2)s, are obviously not the same as substitution generics. So, it is incremental effort, additional effort on gaining market access. But our team has been working hard, building the right expertise and the right relationships into the channels that we target for the product to be able to gain share on a rapid basis. We still expect it to be a Page 7 of 15 November 4, 2026 build-up over the months and quarters. We expect to launch the product in the first quarter of FY28, and as we gain traction in the channels that we have targeted, we expect the share to build up.
Question
Shashank Krishnakumar: If you could just comment on the progress made with respect to some of our respiratory filings, Respimat, Ellipta platforms, etc. Where are we in terms of, I think we had guided to close to seven filings this year. If you could update on the progress , there?
Answer, vinita gupta
Vinita Gupta: We have made really good progress on Respimat ; exhibit batches are done, and the filing is this fiscal year on Spiriva Respimat ®. On the Ellipta franchise, we have had good progress on the Breo product, so that is expected to be filed later this fiscal year. It probably will slip a couple of months into first quarter next fiscal year, but the seven to eight products that we targete d with these two plus the MDIs remain on track to be filed within this fiscal year or within a couple of months of the end of the fiscal year .
Question
Shashank Krishnakumar: The R&D spend for the current year is guided to around 8%. What we have seen in case of some of our peers is probably some optimization of R&D spend, which also has been happening. So sometime next year, FY28, is this also a line item which you could look to optimize given where margins might stand at that point? Or given your focus incrementally on complex filings, you expect R&D spend to remain in this range?
Answer, vinita gupta
Vinita Gupta: Revenue should remain at a billion dollars plus, which is a bar that we want to be able to maintain. In terms of matching levels of FY27, we have some pressures with Tolvaptan coming off with additional competition. Post - September next year, we would expect additional competition on Mirabegron. Apixaban, Dalbavancin and the biosimilars, particularly Pegfilgrastim, should help us grow. We hope to be able to be at least at a billion dollars plus. As we look out in FY29 and get the full-year impact of some of these more durable pipeline products, we would expect the business to grow.
Question
Bino Pathiparampil: Do you have a filing of Etanercept in the U.S., and what is the status?
Answer, vinita gupta
Vinita Gupta: We expect to be in the first wave in 2029. Page 8 of 15 November 4, 2026 Bino Pathiparampil: Europe and Other Markets revenue seem to be pretty weak this quarter.
Question
If I adjust for VISUfarma, it seems to be even down YoY. Is there any particular reason for that?
Answer, vinita gupta
Vinita Gupta: Europe was pretty strong, double digit, even without VISUfarma. The Other Markets, in particular Latin America and Brazil, had additional competition in Dapagliflozin, where we had tremendous upsides over the last two years. That was primarily the reason for the decline in Emerging Market revenues.
Question
Neha Manpuria: On the gross margin number, if I look at the Fx, the Fx has not increased materially QoQ. I think it is up a percent and a half. Also, if you could just give us some colour on what is the exit Tolvaptan market share that we have, to make sense of the gross margin number and how we should think about it going forward. And is it fair that we are expecting one more competitor to come through in Tolvaptan in this quarter?
Answer, vinita gupta
Vinita Gupta: We expect potentially a couple of additional competitors can come in. We had market share of 50% in the last couple of months, being the sole generic in the marketplace. With this additional competition, obviously, we will be giving up some share. The bigger impact is on pricing. We would expect the generic share to continue to grow, and we are certainly continuing to maintain a big percentage of our channel partners but would expect the margin contribution and revenue contribution to come down significantly.
Question
Neha Manpuria: In this context, is Fx the only reason we have been able to offset the Tolvaptan impact on gross margins?
Answer, ramesh swaminathan
Ramesh Swaminathan: When I spoke about forex, it is in the context of forwards that I had taken in the first quarter. When we started the year, it was around 89 to 90. Some of the forwards were around that range. It had depressed overall realizations for the first quarter, which is not there in the second quarter. That is what I meant by tailwinds in the second quarter.
Question
Neha Manpuria: Second question is on Apixaban. I know you said that it is too early for us to say as to what could be the share that we could take, etc. But in your assessment, how easy is it to launch a 505(b)(2) to take this share? When you say incremental effort would be required, would this also mean investment on the ground or additional investment that we would need to make in the coming quarters before the launch?
Answer, vinita gupta
Vinita Gupta: Yes, we are planning to make additional investments in the next couple of quarters to be able to get the right market access and channel expertise and relationships to be able to build share in the exclusive window that we have prior to the generics coming in. In particular, we would expect to retain some Page 9 of 15 November 4, 2026 share after the generics come in segments that benefit from a liquid dosage form. So, we have built in incremental efforts on the commercial front to be able to build share .
Question
Neha Manpuria: Given this is a differentiated dosage, could it be slightly more durable even after generics come in FY29?
Answer, vinita gupta
Vinita Gupta: That is what we are expecting . As we look at the 505(b)(2)s, the thought is that you get a longer window from a business and margin perspective relative to exclusive generics.
Show 19 more questions
Question
Kunal Dhamesha: On the Apixaban strategy, would it be focused more on B2B customers, getting formulary access and then leading to substitution, or would it be more of a B2C strategy?
Answer, nilesh gupta
Nilesh Gupta: For H1, we are 16% ahead of the market, but definitely not where we need to be. We have seen respiratory in particular at very slow growth, which is pulling down the average. Cardiac has slowed a little bit as well, but we continue to be well ahead of the market. Diabetes is where we are excelling. We expect respiratory to pick up. Usually , the second half is better for respiratory. There is no reason why cardiac should not bounce back as well.
Answer, nilesh gupta
Our goal is 20%-30% ahead, so we are short of that. We have some new launches, the business is doing well, and the entire chronic share is solid. We would expect to build back growth.
Question
Kunal Dhamesha: In respiratory, is this slowdown more on tablets or on the inhaler side?
Answer, nilesh gupta
Nilesh Gupta: On the inhaler side. Everybody has been coughing in India the last few months. I think those remain strong. That is not our focus area . Our focus is on the inhalation side, MDI, DPI, and nebulization, and that part has been slower. You seem to see these alternate years of very solid growth and then lower growth. Last year was very solid.
Answer, nilesh gupta
The year before that was actually slower. The year before that was very solid again. There is no sense in this pattern, but I do see it picking up in second half.
Question
Kunal Dhamesha: On capital deployment, we have some room to kind of lever up to add inorganic growth. What are your thoughts in terms of capital deployment priorities beyond capital expenditure?
Answer, ramesh swaminathan
Ramesh Swaminathan: We are an acquisitive company but will be judicious in our choice of investments. Our first choice would be specialty in Europe and America, and equal importance to acquisitions in India, but only at a cost appropriate from our perspective. Page 10 of 15 November 4, 2026 Kunal Dhamesha: Will there be a very active pipeline that we would be looking at right now ?
Answer, ramesh swaminathan
Ramesh Swaminathan: We have entered the ophthalmic space and would like to grow in that space across the globe. India, of course, based again on the proposition. In our overall capital, we would keep the threshold limits of twice the EBITDA . So that would potentially mean about INR 16,000 crore – INR 17,000 crore for debt, and about INR 3,000 crore – INR 4,000 crore that we have on our balance sheet. So, we could go up to INR 20,000 crore really, but the proposition should be compelling enough .
Question
Kunal Randeria: On Xywav®, litigation is still on with the innovator, while one Indian filer has settled. Is this an FY29 opportunity, and do you expect sole or shared exclusivity?
Answer, vinita gupta
Vinita Gupta: It is not FY29; it is a further -out opportunity. We believe we were sole exclusive and first to file. The brand can always launch an authorized generic or partner with companies that they settle with, but we are not privy to those arrangements.
Question
Kunal Randeria: Are Dulera and Diazepam nasal spray still opportunities for next year, and can they be meaningful?
Answer, vinita gupta
Vinita Gupta: We are expecting Diazepam for certain, and hopefully Dulera also, depending on the queries we get from the FDA. Hopefully, it is an opportunity next year or early FY29.
Question
Kunal Randeria: On Apixaban, you may have a 10-month window before ANDA generics hit the market. Are you confident of maintaining or enhancing FY28 Apixaban revenues in 2029 and 2030?
Answer, vinita gupta
Vinita Gupta: We hope so. We will learn a lot through this launch. The time we have prior to generics coming in is likely the most valuable, but we expect to retain share, especially in channels where the liquid dosage form brings real benefit to patients. We hope to have a tail in the coming years.
Question
Shyam Srinivasan: As you prepare to launch these five biosimilars in the U.S., what are some of the learnings that you're seeing the first wave players have gone through the challenges, and when you arrive in the markets, what are you trying to do differently to kind of achieve the kind of stated shares that you have probably achieved on the small molecule side? Is there something that you need to keep in mind from a philosophy perspective of how we approach biosimilars in the U.S.?
Answer, vinita gupta
Vinita Gupta: Our first one, Pegfilgrastim, has launched through our partner Valorum, so we look forward to learning from that experience. As we have seen companies in the market over the last couple of years, it is pretty clear that what tactics and strategies succeed on the biosimilars front are very different from small molecule. Page 11 of 15 November 4, 2026 The erosion on the pricing standpoint, discounting by manufacturers really does not help much on the biosimilars front relative to our small molecule generics. One really needs to carefully look at the incentives to the payers on the biosimilars front that really drive substitution on biosimilar. We are very pleased that we are going to ramp up these products over the next few years at a time when there is significant openness relative to five to eight years ago. Biosimilars were still nascent. Today, there is a pretty active adoption of biosimilars in the marketplace, and a lot of learnings of companies that have exited products as well as come back into the market with different strategies that really inform how we launch the products that we plan to launch over the next few years .
Question
Shyam Srinivasan: On your U.S. guidance, we have done one half at USD 683 million. So even if I take the midpoint of your full year guidance, USD 1.1 billion – USD 1.2 billion, we are talking about like a quarterly run rate of USD 230 million per quarter, right? Is that the kind of like USD 100 million loss that we envisage, or you think Q2 probably has come in far better than what you thought? And the reason to just hold onto that guidance maybe, is there upside risk is the question I am asking?
Answer, vinita gupta
Vinita Gupta: Q2 and Q1 was above our plan. Therefore, we will maintain our guidance and see if we get any upside.
Question
Shyam Srinivasan: On India, prescription business was called out at 14% with 6% volume growth. Chronic business growing faster. If you could help us disaggregate how the chronic business volume growth has been happening as well, and if I were to just keep overall anti-diabetes out - since it's a category, especially semaglutide, started this year. I just want to see excluding that, if you could give us some qualitative colour on the growth?
Answer, nilesh gupta
Nilesh Gupta: I have the value, not the volume. The chronic value growth in H1 is 19.5%, and Q2 is 17.4%. Overall, MAT volume is 8.6%, and H1 was 6.1% volume growth. I would presume most of it would be from chronic. The Semaglutide number is not very large. We are the third-largest generic, but the Semaglutide number is not very large in that volume. I would presume that the volume would be close to that.
Question
Rashmi Shetty: What is the addressable market size of Apixaban oral suspension?
Answer, vinita gupta
Vinita Gupta: The overall brand is USD 10 - plus billion. And we have certain channels that we have targeted that are a good percentage of the market .
Question
Rashmi Shetty: Is it fair to understand that EBITDA margin will not be similar to substitutable generic exclusivity?
Answer, vinita gupta
Vinita Gupta: The EBITDA margin should be attractive. We are expecting a margin like an exclusive product, but with some investment on the commercial front.
Question
Tushar Manudhane: Could you share your thoughts on further development work in the peptide segment, apart from what we have launched for regulated markets, specifically the U.S.?
Answer, vinita gupta
Vinita Gupta: On peptides, the products launched so far are Glucagon and Liraglutide. Over the next couple of years, these will continue to be the material products. We don't expect to get products like semaglutide and others, the newer peptides, the GLP-1s, into the market anytime soon , just given the patent expiry is beyond the five-year timeframe for those products. In the near term, the injectable products that are turning out to be really attractive for us . Risperdal Consta® is one of them. Sugammadex that we just launched is a nice opportunity for us. Dalbavancin, both the 505(b)(2) as well as generic opportunities are nice opportunities for us.
Answer, vinita gupta
Broadly, we look at biosimilars, also injectables. We see larger opportunity on the biosimilars front, even compared to injectables in the next three to five years.
Question
Tushar Manudhane: Similarly, on the iron colloid side?
Answer, vinita gupta
Vinita Gupta: We expect some niche product launches on the iron colloid side as well.
Question
Foram Parekh: First question is on the company -level EBITDA margin. Since we have mentioned about couple of pipeline products, and Apixaban launch would be there in FY28, whose margins would also be like an exclusive product margin. Do we see a company-level EBITDA margin going back to 29%-30% in a span of five years with so many products in pipeline?
Answer, ramesh swaminathan
Ramesh Swaminathan: Yes, if you were to take 2029-30. We could get to those levels. There are investments coming up, but the areas we are entering have very good realizations: 505(b)(2)s, biosimilars and specialty products across the globe, including Yuvezzi. As these scale, we could get to those levels. Secular growth is expected over several quarters, whilst FY28 could potentially be a period of consolidation.
Question
I read in the presentation that on the chronic side, we will max out at 70%, and we have already achieved 66% of our chronic contribution. Assuming that we will achieve target in near term, we will not go beyond 70% on the chronic side. Is that a fair understanding ?
Answer, nilesh gupta
Nilesh Gupta: I would love to prove you wrong. Our plans add up to around 70%, but that does not mean we stop there. We are a chronic story and that is where growth will come from. Consistently, the growth on that side has been higher . Acute and semi-acute parts will also grow, but the focus remains chronic, so theoretically chronic share will keep growing.
Question
Alankar Garude: Are you evaluating the possibility of a partner for Apixaban?
Answer, vinita gupta
Vinita Gupta: We looked at all opportunities and options and believe we have a strong commercial strategy here.
Question
Alankar Garude: On manufacturing front, given the product is filed from Somerset, there is enough capacity available to drive the best outcome in FY28?
Answer, vinita gupta
Vinita Gupta: Yes. Our global operations and supply chain team, as well as the Somerset team, have worked very hard to ensure we can meet our upside scenario.
Question
Alankar Garude: On costs, are there levers such as discretionary spends that could reverse as Tolvaptan contribution comes down?
Answer, ramesh swaminathan
Ramesh Swaminathan: The expenditure increase is essentially because of settlement-related costs on account of Mirabegron which would reverse out. The second is, we are also investing ahead of the curve in terms of IT, a number of platforms and Al spends. We would expect a lot of outcomes to come in from there. There is an investment phase, that would play out over the next few quarters. So, if you were to take a period of time, say three, four years, you would expect the IT spends would increase, but as a percentage of sales, to be much lower. The outcomes from those are visible across various other lines.
Question
Alankar Garude: So, these are more about productivity gains rather than discretionary spends coming down or staying flat in absolute basis?
Answer, ramesh swaminathan
Ramesh Swaminathan: Well, discretionary spends, so it is essentially with better ways of looking at, they are ways of looking at productivity. So clearly, with the advent of technology and the like, a number of things would be made possible.
Answer, vinita gupta
Vinita Gupta: Thank you, friends, for all your questions. Hopefully, we were able to give you all the answers; otherwise, our team will be in touch with any additional clarifications you need. We remain confident in growing our business in a more sustainable manner. Investments in areas like specialty, particularly in Europe, as well as biosimilars and 505(b)(2)s, give us confidence that we should be able to evolve our developed markets business toward a more durable and sustainable portfolio, as opposed to one -off exclusives. Our consistent performance and increased investment in India continue to be a Page 14 of 15 November 4, 2026 strong anchor for growth. We remain excited about our prospects over the next five years and look at the next year as a year of investment and capability building to create a more resilient business. Thank you again for your time today, and we look forward to connecting with you soon.
Questions about this call
- When was the Lupin Q2 FY27 earnings call transcript filed?
- Lupin filed the transcript with the exchange on 6 Nov 2026. This page is built from that transcript.
- What does this page list?
- 106 statements from the transcript across 11 topics, 50 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 29 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.